Acarix and the American College of Cardiology announce strategic collaboration

The American College of Cardiology (“ACC”) and Acarix have signed a strategic collaboration agreement with the goal to develop a clinical framework for the use of cardiovascular acoustic AI-based technology in the United States, the world’s largest market for cardiovascular care.

Within the scope of the collaboration, ACC will provide clinical and scientific expertise to Acarix with the intent to assess the utility and role for acoustic AI-based technology in the US and develop a clinical framework for use of CADScor®System in upstream cardiac diagnostics.

“The agreement with ACC is the most important strategic relationship we have entered so far. Our mission is to make the CADScor®System standard of care to aid rapid chest pain diagnosis and we believe the collaboration with the ACC will help us accelerate the use of our novel technology.” comments Helen Ljungdahl Round, President and CEO of Acarix.

ACC is a US-based nonprofit medical association established in 1949 with more than 56,000 members. ACC issues clinical practice guidelines, provides professional medical education, operates national data registries, and manages data standards and national quality initiatives with the aim to transform cardiovascular care and improve heart health.

Each year, millions of Americans seek healthcare consultations for chest pain. Acarix recently entered the US market following FDA De Novo clearance for its acoustic AI-based CADScor®System to help rapidly and accurately rule-out significant obstructive coronary artery disease in patients with chest pain. The CADScor®System is covered by a dedicated CPT III code 0716T issued in 2021 and effective from July 1, 2022.

For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email
Christian Lindholm, CFO, phone +46 705 118333, email

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix. For more information, please visit

This information is information that Acarix is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-09-26 08:00 CEST.